Staar Surgical Aqua-Flow
This article was originally published in The Gray Sheet
Executive Summary
Premarket approval application submission for the collagen glaucoma drainage device is announced July 6. Clinical data included in the filing show a mean reduction of intraocular pressure from 24.2 mm Hg before placement to 16.5 mm Hg at one-year follow-up. Patients also experienced a mean drop in pressure controlling medications from 2.3 to 0.3, the firm says. Physician training is scheduled to begin in August
You may also be interested in...
Staar Surgical AquaFlow Glaucoma Drainage Device Approvable - FDA Panel
Staar Surgical should collect expanded two-year follow-up data for patients treated with the AquaFlow collagen glaucoma drainage device as a condition of FDA approval, the agency's Ophthalmic Devices Advisory Panel recommended Nov. 8 in Gaithersburg, Maryland.
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.